Alan Auerbach

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 578 citations

5-Year Analysis, Breast Oncology, Oncology +10

The small-caliber esophagus: An unappreciated cause of dysphagia for solids in patients with eosinophilic esophagitis

Sotirios Vasilopoulos, Philip Murphy, Alan Auerbach et al. · Gastrointestinal Endoscopy · 2002 · 168 citations

Esophagus, Medicine, Gastroenterology +5

Hyperactivation of TORC1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in HER2-Mutant Cancers

Dhivya R. Sudhan, Ángel Guerrero‐Zotano, Helen Won et al. · Cancer Cell · 2020 · 49 citations · Full text

Extended Adjuvant Therapy with Neratinib Plus Fulvestrant Blocks ER/HER2 Crosstalk and Maintains Complete Responses of ER+/HER2+ Breast Cancers: Implications to the ExteNET Trial

Dhivya R. Sudhan, Luis J. Schwarz, Ángel Guerrero‐Zotano et al. · Clinical Cancer Research · 2018 · 45 citations

Effects of neratinib on health-related quality of life in women with HER2-positive early-stage breast cancer: longitudinal analyses from the randomized phase III ExteNET trial

Suzette Delaloge, David Cella, Ying-Xuan Ye et al. · Annals of Oncology · 2019 · 25 citations · Full text